NEW YORK--(BUSINESS WIRE)--

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Ocera Therapeutics, Inc. (“Ocera Therapeutics” or the “Company”) (NASDAQ: OCRX) stock prior to November 2, 2017.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ocera Therapeutics to Mallinckrodt plc (NYSE: MNK). Under the terms of the transaction, shareholders of Ocera Therapeutics will receive $1.52 per share plus a Contingent Value Right to receive one or more payments of up to $2.58 per share. To learn more about the action and your rights, go to:

http://www.zlkdocs.com/OCRX-Info-Request-Form-ma-6200

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171102005999/en/